Available to treat adults with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement PEMAZYRE ® (pemigatinib) is available via a co-pay access program in Australia ...
Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify [email protected] if there are concerns ...
Gallbladder cancer and cholangiocarcinoma are both biliary cancers. They can cause the same symptoms, but causes and treatments can differ. Gallbladder cancer is cancer of the gallbladder, while ...
Primary sclerosing cholangitis (PSC) is a rare progressive liver disease that damages bile ducts and significantly increases the risk of bile duct cancer, particularly a type called cholangiocarcinoma ...
Liver cancer screening uses ultrasound and AFP biomarker tests, with CT or MRI for further evaluation if abnormalities are ...
BASKING RIDGE, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for ...
Bile duct cancer is a rare but very aggressive cancer. While survival rates are low, new advances in treatment may improve your life expectancy. Bile duct cancer, also known as cholangiocarcinoma, is ...
Ten years ago, Cholangiocarcinoma was a little known, little understood, rare disease, also known as an orphan cancer. This is no longer the case ever since the Cholangiocarcinoma Foundation was ...
– Using Invitae's Ciitizen patient-driven data platform, AstraZeneca and the Cholangiocarcinoma Foundation will access lived experience of patients with a rare cancer to drive further research – – ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback